Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Pisansky

Showing results (51-60 of 135) with videos related to

Pageof 14
Sort By:
Gastrointestinal Cancer Research : GCR|June 16, 2011
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal CancerLisa A Kachnic, Kathryn Winter, Todd Wasserman, et al.
The New England Journal of Medicine|July 4, 2003
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman, Robert Gray, Nicholas J Robert, et al.
Urology|December 5, 2006
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failureMichael E Ray, Larry B Levy, Eric M Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
JAMA|April 3, 2014
Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trialThomas M Pisansky, Stephanie L Pugh, Richard E Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831Michele Y Halyard, Thomas M Pisansky, Amylou C Dueck, et al.
International Journal of Particle Therapy|June 3, 2024
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate CancerRobert W Gao, Jiasen Ma, Thomas M Pisansky, et al.
The Prostate|April 20, 2012
Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancerMichael G Heckman, Alexander S Parker, Kevin J Wu, et al.
Cancer|September 15, 2020
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) studyCarlos E Vargas, Cameron S Thorpe, Amylou C Dueck, et al.
The British Journal of Radiology|May 10, 2017
GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancerJessica L Robinson, Katherine S Tzou, Alexander S Parker, et al.
Pageof 14

Showing results (51-60 of 135) with videos related to

Sort By:
Pageof 14
Gastrointestinal Cancer Research : GCR|June 16, 2011
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal CancerLisa A Kachnic, Kathryn Winter, Todd Wasserman, et al.
The New England Journal of Medicine|July 4, 2003
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman, Robert Gray, Nicholas J Robert, et al.
Urology|December 5, 2006
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failureMichael E Ray, Larry B Levy, Eric M Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
JAMA|April 3, 2014
Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trialThomas M Pisansky, Stephanie L Pugh, Richard E Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831Michele Y Halyard, Thomas M Pisansky, Amylou C Dueck, et al.
International Journal of Particle Therapy|June 3, 2024
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate CancerRobert W Gao, Jiasen Ma, Thomas M Pisansky, et al.
The Prostate|April 20, 2012
Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancerMichael G Heckman, Alexander S Parker, Kevin J Wu, et al.
Cancer|September 15, 2020
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) studyCarlos E Vargas, Cameron S Thorpe, Amylou C Dueck, et al.
The British Journal of Radiology|May 10, 2017
GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancerJessica L Robinson, Katherine S Tzou, Alexander S Parker, et al.
Pageof 14